Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Campbell, California and currently employs 79 full-time employees. The company went IPO on 2014-02-27. The firm's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The firm delivers QuantaFlo directly to its customers. The firm also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Follow-Up Questions
Semler Scientific Inc (SMLR) の株価収益率はいくらですか？
Semler Scientific Inc の株価収益率は 12.3047 です。
Semler Scientific Inc のCEOは誰ですか？
Dr. Douglas Murphy-chutorian は Semler Scientific Inc の Chief Executive Officer で、2012 から在籍しています。
